Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Bristol Laboratories Limited, Unit 3, Canalside, Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG, United Kingdom
Majoven XL 37.5 mg prolonged release capsules, hard.
Venlafaxine Bristol Labs XL 37.5 mg prolonged release capsules, hard.
| Pharmaceutical Form |
|---|
|
Prolonged-release capsule, hard. Size ‘3’ hard gelatin capsule with peach opaque cap and light grey opaque body filled with white to off white pellets. |
Each prolonged-release capsule contains 42.45 mg of venlafaxine hydrochloride, equivalent to 37.5 mg of venlafaxine free base.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Venlafaxine |
Venlafaxine has an antidepressant effect. The mechanism of its action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system. |
| List of Excipients |
|---|
|
PL 17907/0565 Capsule contents: Microcrystalline cellulose Capsule shell: Gelatin Printing ink: Shellac |
Blister packs of PVC/ACLAR film and Aluminium foil or PVC/PVdC film and Aluminium foil containing 7, 10, 14, 15, 20, 28, 30, 50, 56, 60, 98, 100 capsules.
Not all pack sizes may be marketed.
Bristol Laboratories Limited, Unit 3, Canalside, Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG, United Kingdom
PL 17907/0565
22/09/2016
| Drug | Countries | |
|---|---|---|
| MAJOVEN | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
